MX343505B - Metodos y composiciones para inhibir la transmision del vih. - Google Patents

Metodos y composiciones para inhibir la transmision del vih.

Info

Publication number
MX343505B
MX343505B MX2012011574A MX2012011574A MX343505B MX 343505 B MX343505 B MX 343505B MX 2012011574 A MX2012011574 A MX 2012011574A MX 2012011574 A MX2012011574 A MX 2012011574A MX 343505 B MX343505 B MX 343505B
Authority
MX
Mexico
Prior art keywords
hiv
env
human
protein
fragment
Prior art date
Application number
MX2012011574A
Other languages
English (en)
Spanish (es)
Other versions
MX2012011574A (es
Inventor
Thomas Rawlin Grant
Francis John Purcell Damian
John Center Robert
Kramski Marit
Michael Robins-Browne Roy
Lichti Gottfried
Original Assignee
Immuron Ltd *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuron Ltd * filed Critical Immuron Ltd *
Publication of MX2012011574A publication Critical patent/MX2012011574A/es
Publication of MX343505B publication Critical patent/MX343505B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2012011574A 2010-04-09 2011-04-11 Metodos y composiciones para inhibir la transmision del vih. MX343505B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32239910P 2010-04-09 2010-04-09
PCT/AU2011/000407 WO2011123900A1 (en) 2010-04-09 2011-04-11 Methods and compositions for inhibiting hiv transmission

Publications (2)

Publication Number Publication Date
MX2012011574A MX2012011574A (es) 2013-03-05
MX343505B true MX343505B (es) 2016-11-04

Family

ID=44761932

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012011574A MX343505B (es) 2010-04-09 2011-04-11 Metodos y composiciones para inhibir la transmision del vih.

Country Status (12)

Country Link
US (1) US20130022619A1 (https=)
EP (1) EP2555798B1 (https=)
JP (1) JP6026402B2 (https=)
CN (1) CN103167881B (https=)
AP (1) AP3469A (https=)
AU (2) AU2011238431B2 (https=)
BR (1) BR112012025678A2 (https=)
CA (1) CA2795853A1 (https=)
MX (1) MX343505B (https=)
RU (1) RU2594249C2 (https=)
WO (1) WO2011123900A1 (https=)
ZA (1) ZA201207790B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3049524A4 (en) * 2013-09-27 2017-06-14 Duke University Hiv-1 mother-to-child transmission correlates of protection and vaccine
CN103736100B (zh) * 2013-12-25 2017-06-09 南方医科大学 预防hiv性传播的杀微生物剂酸酐修饰抗sevi多克隆抗体
JP6955487B2 (ja) * 2015-09-24 2021-10-27 アブビトロ， エルエルシー Ｈｉｖ抗体組成物および使用方法
WO2017062071A1 (en) * 2015-10-07 2017-04-13 Eca Medical Instruments Gearless washer spring torque drive
US10973679B2 (en) * 2016-02-12 2021-04-13 Adam Arreola STD detecting condom
JP2023528992A (ja) 2020-06-10 2023-07-06 ザ ユニバーシティー オブ メルボルン Ｈｉｖ－１抗体
US20240262893A1 (en) 2021-05-12 2024-08-08 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
JP2024521987A (ja) 2021-05-12 2024-06-05 アプライド バイオメディカル サイエンス インスティチュート ジスルフィド結合した結合ポリペプチドのスクリーニング及び発現の方法
JP7421610B1 (ja) 2022-08-18 2024-01-24 株式会社マーベラス ゲーム装置
AU2023379740A1 (en) 2022-11-16 2025-05-29 Applied Biomedical Science Institute Fusion polypeptides and binding peptides and methods for producing and using same
WO2026073047A1 (en) 2024-09-27 2026-04-02 Applied Biomedical Science Institute Methods of screening and expressing cis-display libraries of disulfide-rich polypeptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039957A (en) * 1993-12-10 2000-03-21 United States Of America, As Represented By The Department Of Health And Human Services Oligomeric HIV-1 envelope glycoproteins
DK1190101T3 (da) * 1999-06-24 2009-08-03 Univ Johns Hopkins Sammensætninger og fremgangsmåder til at forebygge transepithelial overförsel af HIV
MXPA03002643A (es) * 2000-09-28 2003-06-19 Chiron Corp Composiciones de microparticulas y metodos para producirlas.
US7939083B2 (en) * 2006-10-23 2011-05-10 Progenics Pharmaceuticals Inc. Soluble, stabilized, proteolytically cleaved, trimeric HIV-1 gp140 proteins comprising modifications in the N-terminus of the gp41 ectodomain
WO2009058989A1 (en) * 2007-10-30 2009-05-07 International Aids Vaccine Initiative Antigen-antibody complexes as hiv-1 vaccines
WO2010096042A1 (en) * 2008-10-30 2010-08-26 Dana-Farber Cancer Institute Mimotopes of hiv env

Also Published As

Publication number Publication date
JP2013523783A (ja) 2013-06-17
AP2012006519A0 (en) 2012-10-31
RU2012142999A (ru) 2014-05-20
JP6026402B2 (ja) 2016-11-16
ZA201207790B (en) 2013-06-26
BR112012025678A2 (pt) 2017-07-18
AP3469A (en) 2015-11-30
CN103167881A (zh) 2013-06-19
MX2012011574A (es) 2013-03-05
RU2594249C2 (ru) 2016-08-10
EP2555798B1 (en) 2016-06-22
EP2555798A4 (en) 2013-11-20
US20130022619A1 (en) 2013-01-24
EP2555798A1 (en) 2013-02-13
AU2017265055A1 (en) 2019-06-06
AU2011238431A1 (en) 2012-11-08
CA2795853A1 (en) 2011-10-13
CN103167881B (zh) 2017-06-16
WO2011123900A1 (en) 2011-10-13
AU2011238431B2 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
MX343505B (es) Metodos y composiciones para inhibir la transmision del vih.
EA202190365A1 (ru) Способы изготовления пакетов-мессенджеров растений
CY1123462T1 (el) Αντισωματα που εξουδετερωνουν ισχυρα τον ιο ηπατιτιδας β και χρησεις αυτων
CY1121672T1 (el) Αντισωματα που προσδενουν τα il-17a και il-17f
JP2013523783A5 (https=)
MX2020011717A (es) Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas.
CY1121323T1 (el) Αντισωματα εξουδετερωσης του ιου ανθρωπινης ανοσοανεπαρκειας (hiv)
CY1116835T1 (el) Νεο ευρωπαϊκο στελεχος toy prrsv
PH12016501672A1 (en) Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia
MX2021006756A (es) Anticuerpos que neutralizan el virus de la hepatitis b y usos de los mismos.
MX2013004159A (es) Proteina vp6 de la capside de norovirus y de rotavirus para el uso como vacuna combinada.
EA201892233A1 (ru) Композиции и способы, связанные с иммуногенами вич-1
EA201692279A1 (ru) Способ уменьшения иммуногенности белка и пептида
WO2011106100A3 (en) Method of inducing the production of protective anti-hiv-1 antibodies
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
Valdez et al. Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains
MX2022005498A (es) Vacuna del zika/dengue y aplicación de la misma.
EP3830108A4 (en) GENETIC ANTIBODIES AGAINST HIV-ENV
WO2016130560A3 (en) Cross-reactive t cell epitopes of hiv, siv, and fiv for vaccines in humans and cats
PH12020500414A1 (en) Method for producing influenza ha split vaccine
IN2015DN03026A (https=)
MY207887A (en) Method for improving immunogenicity of protein/peptide antigen
MY208974A (en) Method for preparing influenza ha split vaccine
CY1118067T1 (el) Μεθοδος για τη ληψη ενος τριπλοειδους διαειδικου υβριδιου απο μυλοκοπι και στικτομυλοκοπι
MX2024015797A (es) Metodos para el tratamiento de esofagitis eosinofilica en pacientes pediatricos mediante la administracion de un antagonista de il-4r

Legal Events

Date Code Title Description
FG Grant or registration